French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected ...

PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.

Sanofi announces buy back of shares from L’OréalParis, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from ...

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares closed yesterday at $108.00. According to TipRanks ...

Sanofi SAN-0.15%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 billion), to be completed between now and the end of December 2025. Sanofi ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

This was CNBC’s live blog covering all the latest news, views and action on Day 4 of the World Economic Forum in Davos, ...

Other challenged products include Perrigo's Firefly anti-cavity rinse and Sanofi's ACT Kids rinse. The proposed class actions cite warnings from U.S. health regulators that fluoride-based ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic ...